Wednesday - January 07, 2026

Category Archives: Pharmaceuticals & Biotech

Non-Cystic Fibrosis Bronchiectasis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed

The Key Non-Cystic Fibrosis Bronchiectasis Companies in the market include – Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others.   DelveInsight’s “Non-Cystic … Continue reading →

Vitiligo Market Set for Robust Expansion Through 2034, DelveInsight Reports | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech

The Key Vitiligo Companies in the market include – Incyte, Abbvie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others.   The Vitiligo market is expected … Continue reading →

Peanut Allergy Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Stallergenes Greer, Roch, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics

The Key Peanut Allergy Companies in the market include – Stallergenes Greer, Roche and Novartis, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics, and others.   DelveInsight’s “Peanut Allergy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth … Continue reading →

Treatment-resistant Hypertension Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics

The Key Treatment-resistant Hypertension Companies in the market include – Idorsia Pharmaceuticals, Ionis Pharmaceuticals, KBP Biosciences, Quantum Genomics, CinCor Pharma, Idorsia Ltd., Janssen Biotech, and others. The Treatment-resistant Hypertension market is expected to surge due to the disease’s increasing prevalence … Continue reading →

Metastatic Uveal Melanoma Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Metastatic Uveal Melanoma Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Metastatic Uveal Melanoma, historical and forecasted epidemiology as well as the Metastatic Uveal Melanoma market trends in the United States, EU4 (Germany, … Continue reading →

Sjogren’s Syndrome Market Size (7MM) was ~USD 1,900 million in 2023 and it is expected to grow by 2034, estimates DelveInsight

DelveInsight’s “Sjogren’s Syndrome Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Sjogren’s Syndrome, historical and forecasted epidemiology as well as the Sjogren’s Syndrome market trends in the United States, EU4 (Germany, France, Italy, and … Continue reading →

Multiple System Atrophy Market in the 7MM is projected to grow at a CAGR of 50.60% by 2034, estimates DelveInsight

DelveInsight’s “Multiple System Atrophy Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Multiple System Atrophy, historical and forecasted epidemiology as well as the Multiple System Atrophy market trends in the United States, EU4 (Germany, … Continue reading →

IgA Nephropathy Market Expected to Gain Momentum Through 2034, According to DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharma, Rohto

The Key IgA Nephropathy Companies in the market include – Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui … Continue reading →

FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why

Synergy CHC Corp. (NASDAQ: SNYR) is gaining renewed investor attention as its FOCUSfactor® functional beverage platform scales rapidly through the Company’s already-established retail ecosystem—built on the strength of its 25-year FOCUSfactor® brain health supplement legacy. By leveraging long-standing national distribution … Continue reading →